TY - JOUR
T1 - Estrogen and progesterone receptor testing in breast cancer
T2 - ASCO/CAP guideline update
AU - Allison, Kimberly H.
AU - Hammond, M. Elizabeth H.
AU - Dowsett, Mitchell
AU - McKernin, Shannon E.
AU - Carey, Lisa A.
AU - Fitzgibbons, Patrick L.
AU - Hayes, Daniel F.
AU - Lakhani, Sunil R.
AU - Chavez-MacGregor, Mariana
AU - Perlmutter, Jane
AU - Perou, Charles M.
AU - Regan, Meredith M.
AU - Rimm, David L.
AU - Symmans, W. Fraser
AU - Torlakovic, Emina E.
AU - Varella, Leticia
AU - Viale, Giuseppe
AU - Weisberg, Tracey F.
AU - McShane, Lisa M.
AU - Wolff, Antonio C.
N1 - Publisher Copyright:
© 2020 by American Society of Clinical Oncology
PY - 2020/4/20
Y1 - 2020/4/20
N2 - PURPOSE To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed by a systematic review of the medical literature. RECOMMENDATIONS The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose. Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive. However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive. Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment. A sample is considered ER negative if, 1% or 0% of tumor cell nuclei are immunoreactive. Additional strategies recommended to promote optimal performance, interpretation, and reporting of cases with an initial low to no ER staining result include establishing a laboratory-specific standard operating procedure describing additional steps used by the laboratory to confirm/adjudicate results. The status of controls should be reported for cases with 0% to 10% staining. Similar principles apply to PgR testing, which is used primarily for prognostic purposes in the setting of an ER-positive cancer. Testing of ductal carcinoma in situ (DCIS) for ER is recommended to determine potential benefit of endocrine therapies to reduce risk of future breast cancer, while testing DCIS for PgR is considered optional. Additional information can be found at www.asco.org/breastcancer-guidelines.
AB - PURPOSE To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed by a systematic review of the medical literature. RECOMMENDATIONS The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose. Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive. However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive. Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment. A sample is considered ER negative if, 1% or 0% of tumor cell nuclei are immunoreactive. Additional strategies recommended to promote optimal performance, interpretation, and reporting of cases with an initial low to no ER staining result include establishing a laboratory-specific standard operating procedure describing additional steps used by the laboratory to confirm/adjudicate results. The status of controls should be reported for cases with 0% to 10% staining. Similar principles apply to PgR testing, which is used primarily for prognostic purposes in the setting of an ER-positive cancer. Testing of ductal carcinoma in situ (DCIS) for ER is recommended to determine potential benefit of endocrine therapies to reduce risk of future breast cancer, while testing DCIS for PgR is considered optional. Additional information can be found at www.asco.org/breastcancer-guidelines.
UR - http://www.scopus.com/inward/record.url?scp=85082800301&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082800301&partnerID=8YFLogxK
U2 - 10.1200/JCO.19.02309
DO - 10.1200/JCO.19.02309
M3 - Article
C2 - 31928404
AN - SCOPUS:85082800301
SN - 0732-183X
VL - 38
SP - 1346
EP - 1366
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 12
ER -